Effects of donepezil on activities of daily living: Integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease

International Psychogeriatrics

Volumn 22, Issue 6, 2010, Pages 973-983

  Gauthier, Serge ^a   Lopez, Oscar L ^b   Waldemar, Gunhild ^c   Jones, Roy W ^d   Cummings, Jeffrey ^e   Zhang, Richard ^f   Schindler, Rachel ^f   Schwam, Elias ^f  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF BATH   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PFIZER INC   (United States)

Author keywords

activities of daily living; Alzheimer's disease; donepezil; functional scales; treatment effect

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASSISTED LIVING FACILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NURSING HOME; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STANDARDIZATION; VALIDATION STUDY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMBULATORY CARE; ASSISTED LIVING FACILITIES; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NOOTROPIC AGENTS; PIPERIDINES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKILLED NURSING FACILITIES;

EID: 77957313578     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610210000888     Document Type: Article

References (20)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Press.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. 4th edn, text revision. Washington, DC: American Psychiatric Association Press.
3. Burns, A. et al. (1999). The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dementia and Geriatric Cognitive Disorders, 10, 237-244.
4. Cullum, C. M. et al. (2001). Performance-based instrument to assess functional capacity in dementia: the Texas Functional Living Scale. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 14, 103-108.
5. Donaldson, S. W., Wagner, C. C. and Gresham, G. E. (1973). A unified ADL evaluation form. Archives of Physical Medicine and Rehabilitation, 54, 175-179.
6. Feldman, H. et al. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613-620.
7. Feldman, H. et al. (2003). Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. Journal of the American Geriatrics Society, 51, 737-744.
8. Feldman, H. H., Van Baelen, B., Kavanagh, S. M. and Torfs, K. E. (2005). Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Disease and Associated Disorders, 19, 29-36.
9. Galasko, D. et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11, S33-S39.
10. Gelinas, I., Gauthier, L., McIntyre, M. and Gauthier, S. (1999). Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. American Journal of Occupational Therapy, 53, 471-481.
11. Hill, J., Fillit, H., Thomas, S. K. and Chang, S. (2006). Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics, 24, 265-280.
12. Lawton, M. P. and Brody, E. M. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 9, 179-186.
13. McKhann, G. et al. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
14. Mohs, R. C. et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481-488.
15. Rogers, S. L., Friedhoff, L. T. and the Donepezil Study Group (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293-303.
16. Severson, M. A. et al. (1994). Patterns and predictors of institutionalization in community-based dementia patients. Journal of the American Geriatrics Society, 42, 181-185.
17. Tariot, P. N. et al. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society, 49, 1590-1599.
18. Teunisse, S., Mayke, M., Derix, A. and van Crevel, H. (1991). Assessing the severity of dementia. Patient and Caregiver. Archives of Neurology, 48, 274-277.
19. Winblad, B. et al. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57, 489-495.
20. Winblad, B. et al. (2006). Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367, 1057-1065.